BTS
ABBV icon

BB&T Securities’s AbbVie ABBV Stock Holding History

BB&T Securities’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$73M Buy
964,037
+37,957
+4% +$2.6M 0.67% 29
2019
Q2 		$67.3M Buy
926,080
+65,692
+8% +$5.16M 0.61% 31
2019
Q1 		$69.3M Buy
860,388
+91,518
+12% +$7.49M 0.67% 23
2018
Q4 		$70.9M Buy
768,870
+76,644
+11% +$6.74M 0.79% 17
2018
Q3 		$65.5M Buy
692,226
+13,485
+2% +$1.28M 0.65% 23
2018
Q2 		$62.9M Buy
678,741
+13,040
+2% +$1.27M 0.67% 24
2018
Q1 		$63M Sell
665,701
-15,991
-2% -$1.76M 0.71% 19
2017
Q4 		$65.9M Sell
681,692
-64,859
-9% -$6.11M 0.86% 14
2017
Q3 		$66.3M Sell
746,551
-56,271
-7% -$4.28M 0.9% 11
2017
Q2 		$58.2M Sell
802,822
-407,735
-34% -$27.4M 0.84% 13
2017
Q1 		$78.9M Sell
1,210,557
-40,387
-3% -$2.54M 1.08% 11
2016
Q4 		$78.8M Sell
1,250,944
-67,196
-5% -$4.1M 1.14% 10
2016
Q3 		$83.1M Sell
1,318,140
-110,535
-8% -$7.16M 1.24% 7
2016
Q2 		$88.4M Buy
1,428,675
+49,126
+4% +$2.99M 1.37% 3
2016
Q1 		$78.8M Buy
1,379,549
+436,945
+46% +$24.4M 1.29% 6
2015
Q4 		$55.8M Buy
942,604
+324,345
+52% +$18.7M 1.17% 9
2015
Q3 		$33.6M Buy
618,259
+28,676
+5% +$1.87M 0.74% 36
2015
Q2 		$39.6M Sell
589,583
-6,227
-1% -$407K 0.84% 30
2015
Q1 		$34.9M Sell
595,810
-8,343
-1% -$504K 0.76% 32
2014
Q4 		$39.5M Sell
604,153
-12,657
-2% -$798K 0.89% 27
2014
Q3 		$35.6M Sell
616,810
-108,648
-15% -$6.03M 0.83% 32
2014
Q2 		$40.9M Buy
725,458
+42,730
+6% +$2.24M 0.98% 26
2014
Q1 		$35.1M Sell
682,728
-45,522
-6% -$2.3M 0.91% 33
2013
Q4 		$38.5M Buy
728,250
+31,170
+4% +$1.53M 1.06% 28
2013
Q3 		$31.2M Buy
697,080
+16,881
+2% +$748K 0.97% 31
2013
Q2 		$28.1M Buy
+680,199
New +$29.7M 0.92% 33

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

BB&T Securities's ABBV Position: Q3 2019 in Review

BB&T Securities increased its AbbVie (ABBV) stake by 4.1% in Q3 2019, buying an estimated $2.6M and bringing the position to 964,037 shares worth $73M. The position accounts for 0.67% of the portfolio, ranked #29.

BB&T Securities first reported a position in ABBV in Q2 2013 and has held it in 26 quarters since. The position peaked at $88.4M in Q2 2016. 2,003 funds tracked by Wall St. Rank hold ABBV as of Q3 2019.

  • BB&T Securities held 964,037 shares of AbbVie worth $73M as of Q3 2019.
  • BB&T Securities bought 37,957 AbbVie shares in Q3 2019, an estimated $2.6M.
  • AbbVie made up 0.67% of BB&T Securities's portfolio in Q3 2019, its #29 holding.
  • BB&T Securities first reported a position in AbbVie in Q2 2013 and has held it in 26 quarters since.
  • BB&T Securities's AbbVie position peaked at $88.4M in Q2 2016.
  • 2,003 funds tracked by Wall St. Rank held AbbVie as of Q3 2019.

Based on BB&T Securities's 13F filing for Q3 2019, filed 30 Oct 2019.